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The Akt inhibitor KP372-1 suppresses Akt activity and cell
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The phosphatidylinositol 30 kinase (PI3K)/phosphatase and tensin homologue deleted on chromosome ten/Akt pathway, which is a
critical regulator of cell proliferation and survival, is mutated or activated in a wide variety of cancers. Akt appears to be a key central
node in this pathway and thus is an attractive target for targeted molecular therapy. We demonstrated that Akt is highly
phosphorylated in thyroid cancer cell lines and human thyroid cancer specimens, and hypothesised that KP372-1, an Akt inhibitor,
would block signalling through the PI3K pathway and inhibit cell proliferation while inducing apoptosis of thyroid cancer cells. KP372-1
blocked signalling downstream of Akt in thyroid tumour cells, leading to inhibition of cell proliferation and increased apoptosis. As
thyroid cancer consistently expresses phosphorylated Akt and KP372-1 effectively blocks Akt signalling, further preclinical evaluation
of this compound for treatment of thyroid cancer is warranted.
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The incidence of thyroid cancer in the United States is expected to
be approximately 23 600 in 2004 (Jemal et al, 2004). Thyroid
carcinomas can be classified into papillary thyroid carcinoma,
follicular thyroid carcinoma, and anaplastic thyroid carcinoma
(Jemal et al, 2004). The papillary and follicular thyroid carcinomas
constitute the majority of thyroid carcinomas and are grouped
together as well-differentiated thyroid carcinomas. This group of
thyroid carcinomas can often be cured with surgical resection and
with radioactive iodide therapy. However, there are no effective
alternative therapies for patients with metastatic well-differen-
tiated thyroid cancer who do not respond to radioactive iodine
therapy, suggesting an urgent need for development of novel
therapies.
The pathogenesis of thyroid cancer is characterised by the
alterations of multiple signalling pathways and by abnormalities in
a variety of tumour-suppressor genes and cell-cycle proteins
(Fagin, 2002). The activation of the Akt protein kinase B (Akt/PKB)
signalling pathway appears to play an important role in the
development and progression of thyroid tumours. Interestingly,
Akt has been found to be activated by a genetic loss of expression
of phosphatase and tensin homologue deleted on chromosome
ten (PTEN), a tumour-suppressor gene, in Cowden’s syndrome,
an autosomal dominant multi-organ hamartoma syndrome
characterised by benign and malignant thyroid tumours and
breast and colon cancers (Dahia et al, 1997; Liaw et al, 1997).
Akt activation, probably through a variety of mechanisms
including aberrant stimulation of upstream cancers, occurs in
most sporadic thyroid cancers (Ringel et al, 2001). In benign
thyroid cell models, Akt signalling is important for cell growth in
response to insulin, insulin-like growth factor-1, and serum
(Kimura et al, 1999, 2001; Coulonval et al, 2000; Saito et al,
2001) and is activated by several oncogenes involved in thyroid
cancer, including activated p21ras and chimeric rearrangements
involving the ret gene (RET/PTC oncogenes) (Borrello et al, 1994;
Rodriguez-Viciana et al, 1994). Despite the central role for Akt
activation in thyroid tumorigenesis, little is known about the
biological effect of inhibition of the Akt kinase in the progression
of thyroid carcinoma.
Based on the putative central role of the Akt kinase in thyroid
oncogenesis, we hypothesised that KP372-1, a specific Akt kinase
inhibitor (molecular weight, 224.20; QLT Inc., Vancouver, BC,
Canada), would inhibit the proliferation and induce apoptosis of
thyroid cancer cells in vitro. KP372-1 was identified in a screen of
kinase-inhibiting compounds tested on more than 100 different
cellular kinases, and was selected for its high specificity for the Akt
kinase (unpublished data from QLT). In this study, we demon-
strated the key role of the phosphatidylinositol-3 kinase (PI3K)/
Akt pathway in thyroid cancer and explored the effect of KP372-1
using thyroid cancer cells as model systems. We assessed the
effects of KP372-1 on the inhibition of the PI3K/Akt pathway
biochemically and on cell proliferation and apoptosis.
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MATERIALS AND METHODS
Cell lines
A papillary thyroid carcinoma cell line, NPA187, a follicular
thyroid cancer cell line, WRO, and anaplastic thyroid cancer cell
lines KAT4, C643, K18, HTH74, ARO, and DRO were used. NPA187
and WRO were obtained from Dr Yan Oh, The University of Texas
MD Anderson Cancer Center, Houston, TX, USA, and KAT4, C643,
K18, HTH74, and DRO were obtained from Dr Sai-Ching Jim
Yeung, Department of Endocrine Neoplasia and Hormonal
Disorders, MD Anderson Cancer Center, Houston, TX, USA. All
the cell lines were grown in RPMI medium supplemented with 10%
foetal bovine serum, L-glutamine, penicillin, sodium pyruvate,
nonessential amino acids, and vitamin solution (Life Technologies,
Inc., Grand Island, NY, USA). Adherent monolayer cultures were
maintained on plastic and incubated at 371C in 5% carbon dioxide
and 95% air. The cultures were free of Mycoplasma species. The
cultures were maintained no longer than 12 weeks after recovery
from frozen stocks.
Compounds
KP372-1 (Figure 1) was synthesised by QLT Inc., Vancouver, BC,
Canada. KP372-1 is a mixture of two isomers present in
approximately equal amounts. A stock solution of KP372-1 for
enzyme or cellular assays was prepared in dimethyl sulphoxide
(DMSO) and then diluted in the medium. The final concentration
of DMSO in the incubation mixture did not exceed 0.1% v v1.
Tissue samples and Western blotting
Fresh frozen human thyroid tissue specimens were obtained from
the thyroid tissue bank (The University of Texas MD Anderson
Cancer Center) with the approval of the Institutional Review Board
at the MD Anderson Cancer Center. Thyroid specimens from
patients who had undergone surgery were carefully harvested by
an experienced pathologist (AKE) and were snap frozen in liquid
nitrogen and stored at 801C. Thawed tissue samples were
homogenised in Triton X-100 lysis buffer (20 mM HEPES, 50 mM
NaCl, 1% Triton X-100, 0.1% deoxycholate, 2 mM EDTA, 2 mM
sodium vanadate, and protease inhibitor cocktail), and equal
amounts of protein were analysed by Western blotting. The
following antibodies were used for Western blotting: rabbit anti-
pAkt (S473), rabbit anti-pAkt (T308), and rabbit anti-Akt (Cell
Signaling, Beverly, MA, USA), rabbit anti-p85 and rabbit anti-
PTEN (Santa Cruz, Santa Cruz, CA, USA), and rabbit anti-b-actin
(Sigma, St Louis, MO, USA). b-Actin was used as a loading control.
Cell proliferation
For MTT assays involving treatment with KP372-1, the cells were
diluted to 1000 cells per 100 ml of complete medium, from which
100ml was added to each well of a 96-well plate (Falcon; Becton-
Dickinson, Franklin Lakes, NJ, USA). On the following day, 100 ml
of medium supplemented with two times the desired concentration
of KP372-1 was added to the appropriate wells. The cells were then
kept at 371C in 5% CO2 for 72 h. At this point, 10 ml of a 5 mg ml
1
stock solution of MTT (Sigma) dissolved in water was added to
each well, and the plates were returned to the 371C incubator for
2 h. The supernatant was aspirated out of each well, and 200ml of
DMSO was added to each well. The plates were then shaken for
5 min and the optical density measured at 570 nm using a
spectrophotometer.
To measure the cell proliferation, we plated the NPA187 and
WRO cells at a concentration of 1 104 cells well1 in six-well
plates. The cells were then treated with KP372-1 at a concentration
of 30 and 60 nM for NPA187 and WRO cell lines, respectively, and
were counted using a haemocytometer on days 1, 2, and 3.
3H-thymidine incorporation
DNA synthesis in the control and KP372-1-treated cells was
assessed by the incorporation of 3H-thymidine into newly
replicated DNA. NPA187 and WRO cells were plated at a
concentration of 5000 cells well1 in 96-well plates. After 24 h, the
cells were treated with different concentrations of KP372-1 for 48 h
and treated with 5-mCi ml1 3H-thymidine during the last 2 h (NEN
Life Science Products, Inc., Boston, MA). Cells were washed with
PBS and then extracted with 0.1 N KOH and counted by liquid
scintillation.
DNA fragmentation assay
For the DNA fragmentation assay, low-molecular-weight DNA was
prepared (Mandal et al, 1996). Briefly, NPA187 and WRO cells
(3 106 per plate) were seeded in 100 mm plates and treated with
KP372-1 (30 nM for NPA187 and 60 nM for WRO) for 1, 2, or 3 days.
Both floating and attached cells were scraped and collected in
medium, washed three times with PBS, and resuspended in 1 ml of
lysis buffer (20 mM Tris-HCl (pH 8), 10 mM EDTA (pH 8), and 0.5%
Triton X-100). After incubation on ice for 30 min, the lysates were
spun at 12 000 rpm in a microcentrifuge for 10 min. Low-
molecular-weight DNA in the supernatant was extracted with
equal volumes of phenol and chloroform for 1 h at 41C.
Ammonium acetate (2 M) was added to the aqueous phase, and
the DNA was precipitated with two volumes of ethanol at 201C
overnight. The DNA was treated with RNAse A (1 mg ml1) at 371C
for 1 h, and total DNA was analysed using 1.5% agarose gel and
visualised with ethidium bromide staining.
Western blot analysis of thyroid carcinoma cell lines after
treatment with KP372-1
In order to show the induction of apoptosis-related proteins by
KP372-1, NPA187 and WRO cells (3 106 per plate) were seeded in
100 mm plates and treated with KP372-1 (30 nM for NPA and 60 nM
for WRO) for 1, 2, or 3 days. Both floating and attached cells were
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Figure 1 Molecular structure of KP372-1.
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scraped and collected in medium, washed three times with PBS,
and the cells were lysed in Nonidet P-40 lysis buffer (50 mM Tris-
HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 50 mM
NaF, 10 mM b-glycerol phosphate) containing 1 mM sodium
vanadate, 1 mM phenylmethylsulphonyl fluoride, 10 mg ml1 apop-
tinin, and lysis buffer (20 mM Tris-HCl (pH 8), 10 mM EDTA (pH
8), and 0.5% Triton X-100). After incubation on ice for 30 min, the
lysates were spun at 12 000 rpm in a microcentrifuge for 10 min.
Equal amounts of protein were then analysed by Western blotting
using the following antibodies: mouse anti-poly(ADP-ribose)poly-
merase (PARP) antibody (Trevigen, Gaithersburg, MD, USA),
rabbit anti-caspase-3 antibody (Cell Signaling), and rabbit anti-b
actin antibody (Sigma). b-Actin was used as a loading control.
In order to show the effect of KP372-1 on various signal
transduction pathways in thyroid carcinoma cell lines, we
performed Western blot analysis on NPA187 and WRO cells after
treating the cells with KP372-1. The cells were plated as described
above. After treating the cells with KP372-1 (30 nM for NPA187 and
60 nM for WRO) for 4 h, both floating and attached cells were
scraped and collected in medium, washed three times with PBS,
and lysed with a lysis buffer as described above. After incubation
on ice for 30 min, the lysates were spun at 12 000 rpm in a
microcentrifuge for 10 min. Equal amounts of protein were then
analysed by Western blotting using the following antibodies: rabbit
anti-pAkt (S473), rabbit anti-Akt, rabbit anti-p-mitogen-activated
protein kinase (MAPK), rabbit anti-pmTOR, rabbit anti-pS6R, and
rabbit anti-S6R (Cell Signaling).
Akt enzyme assay to detect in vitro kinase activity
Cells were lysed using the lysis buffer provided in the Akt enzyme
assay kit (Cell Signaling). The cells were scraped and placed in an
Eppendorf centrifuge tube incubated on ice for 15 min and spun in
a centrifuge at 41C for 15 min at full speed. The lysates were then
transferred to a new tube and stored at 801C until assayed.
Immunoprecipitation was carried out as follows: 500 mg of
protein was added to 5 ml of anti-Akt antibody (Cell Signaling) and
rotated at 41C overnight. Protein A sepharose beads (50 ml) were
then added and rotated for 3 h at 41C. The protein A sepharose
beads were then washed three times with lysis buffer and three
times with the 1 kinase buffer provided in the kit. Then the
beads were aspirated, and 40 ml of kinase buffer was supplemented
with 200mM ATP and a mixture (1mg per 40 ml) of fusion protein
(provided in the kit). The tubes were then incubated at 301C for
30 min, after which 20 ml of 3 sample buffer consisting of
187.5 mM Tris-HCl (pH 6.8), 6% (w v1) sodium dodecyl sulphate
(SDS), 30% glycerol, 150 mM DTT, and 0.03% (w v1) bromophe-
nol blue was added to each tube. The tubes were then boiled for
5 min at 951C, and glycogen synthetase kinase-3 (GSK-3)
phophorylation was measured using phospho antibodies (Cell
Signaling).
RESULTS
Akt is phosphorylated in many thyroid cancer cell lines
In an attempt to delineate the role of Akt signalling in thyroid
cancer cells, we first profiled the expression of pAkt, total Akt, and
the p85 subunit of PI3K in a panel of thyroid cancer cell lines. As
seen in Figure 2, most thyroid cancer cell lines expressed readily
detectable levels of pAkt-Ser473, pAkt-Thr308, total Akt, and
subunits of the PI3K p85. PTEN was present in all the cell lines.
The low levels of pAkt in some cell lines was likely due to the
relative levels of pAkt rather than complete absence of this
molecule. Three cell lines were selected for further characterisa-
tion: NPA187, which expressed relatively high levels of pAkt, and
total Akt, K18, which expressed high levels of pAkt and low levels
of total Akt, and WRO, which expressed lower levels of pAkt with
high levels of total Akt. The presence of similar amounts of PTEN
(most mutant PTEN molecules are unstable) in these cell lines
suggests that the difference in pAKT levels was likely not due to
defective PTEN function.
Akt expression in human thyroid cancer tissues
After profiling the expression of Akt and pAkt in thyroid cancer
cell lines, we focused our attention on the role of Akt in well-
differentiated thyroid carcinoma in subsequent experiments. To
determine whether our in vitro findings with cell lines reflected the
biology of human thyroid cancer in vivo, we evaluated the
expression of Akt and pAkt in fresh papillary thyroid tumour
specimens using Western blotting. The status of Akt activation was
examined using a phosphorylation-specific antibody against pAkt-
Ser473 and antibody against total Akt in thyroid tumours and
adjacent normal-appearing tissues. As shown in Figure 3, six of
eight tumours had higher levels of phosphorylated Akt-Ser473
than did normal tissues despite similar levels of total Akt. Akt
phosphorylation was higher in the thyroid tumours than in the
neighbouring normal tissues, suggesting a potential role for Akt
phosphorylation in the carcinogenesis of thyroid cancer. The high
levels of Akt phosphorylation in neighbouring tissue samples from
some patients may reflect a ‘field effect’ due to genetic aberrations
or, alternatively, the production and action of paracrine growth
factors by the tumours.
KP372-1 inhibits proliferation and induces the apoptosis of
thyroid cancer cells in vitro
The effect of KP372-1 on the growth of NPA187 and WRO cells was
evaluated using an MTT assay, cell counting, and 3H-thymidine
incorporation. The proliferation of these cell lines was inhibited by
KP372-1 with an IC50 (concentration at which 50% inhibition
occurs) of 30 and 60 nM for NPA187 and WRO, respectively
(Figure 4). The proliferation of the cell lines was also inhibited by
KP372-1, as evidenced by cell counting (Figure 5A and B) and the
3H-thymidine incorporation assay (Figure 5C and D). As shown in
Figure 2, different levels of pAkt and total Akt were seen in the
three cell lines. As shown in Figure 4, the NPA187 cell line, which
had high basal pAkt levels, was more sensitive to KP372-1 than was
WRO, which had low pAkt levels, suggesting that high pAkt could
indicate cell dependence on this pathway and thus higher
sensitivity to the inhibition of Akt.
This decreased MTT incorporation can be due to a decreased
rate of cell cycle transit or increased cell death. To assess the latter
possibility, we treated the NPA187 and WRO cells with KP372-1 for
different lengths of time and determined the extent of apoptosis by
DNA fragmentation (Figure 6A) and the accumulation of a sub-G0/
G1 cell population by flow cytometry (data not shown). The effect
of KP372-1 on the status of PARP and caspase-3 was also examined
(Figure 6B). The induction of activated caspase-3 and cleavage of
PARP by KP372-1 treatment were observed in both cell lines,
although with different kinetics and different magnitudes. Con-
sistent with the MTT data, NPA187 demonstrated greater degrees
of PARP cleavage and DNA degradation at 72 hours than WRO.
To determine the duration of exposure to KP372-1 required to
commit cells to apoptosis, NPA187 and WRO cells were incubated
with 30 and 60 nM of KP372-1, respectively, for 6 h in serum-free
medium. The cells were then washed with PBS and grown in
medium containing 10% FBS without the inhibitor for another 24
or 48 h. The cells were then assayed for the percentage of apoptotic
cell death. Apoptosis was not induced under these conditions (data
not shown). Thus, we concluded that KP372-1 must be present
continuously in order to induce apoptosis at least at these doses
and for these cell lines.
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KP372-1 inhibits Akt kinase activity, phosphorylation of
Akt, and downstream targets of Akt in thyroid cancer cells
We next determined the effect of KP372-1 on the phosphorylation
of AKT (Ser473) and on downstream targets of Akt, including
p-mTOR and p-S6 ribosomal protein (Ser240/244), and MAPK. We
treated NPA187 and WRO cells with KP372-1 at their respective
IC50 for 4 h and analysed the cell lysates with the specific
antibodies indicated in Figure 7A. In the case of NPA187
and WRO, phosphorylation of Akt and S6 ribosomal protein
was downregulated by treatment with KP372-1. However, the
phosphorylation of mTOR and MAPK was not changed by
treatment with KP372-1. Akt kinase activity was also down-
regulated by KP372-1 in multiple thyroid cancer cell lines,
as tested by an in vitro kinase assay using GSK-b as substrate
(Figure 7B).
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Our results indicate that KP372-1 blocks Akt kinase activity,
thereby decreasing phosphorylation of the S6 ribosomal protein.
The mechanism resulting in the decrease in Akt phosphorylation is
under exploration, but may represent an allosteric change in the
molecule, decreasing access to upstream kinases or increasing
access to downstream phosphatases.
DISCUSSION
Our study shows that thyroid cancer cells expressed detectable
levels of Akt Ser473, Akt-Thr308, total Akt, PTEN, and the p85
subunits of the PI3K and Akt kinase activity. Most of the tumours
showed a higher level of Akt-Ser473 phosphorylation than
matching normal tissues, suggesting an association between a
high level of Akt phosphorylation and thyroid carcinogenesis. This
association was further supported by evidence that blockade of Akt
signalling with the selective inhibitor KP372-1 induced apoptosis
and inhibited cell proliferation in human thyroid cancer cell lines
in culture. Furthermore, KP372-1 was found to inhibit the
phosphorylation and kinase activities of Akt in addition to the
phosphorylation of downstream substrates. However, the mechan-
ism responsible for decreased Akt phosphorylation is not clear. It
is possible that the binding of KP372-1 to Akt may alter its
conformation so that the relevant amino-acid residues are not
available for phosphorylation. A similar effect has been seen with
other inhibitors such as those for MEK1 and JNK where they
decrease phosphorylation of their target in cells with an activated
pathway.
In our study, we found that the papillary thyroid cancer cell line
NPA187 was more sensitive to the effects of KP372-1 compared
with the follicular cell line WRO. However, Ringel et al (2001)
found that the cell line NPA187 was more sensitive than WRO to
the effects of LY294002, a phosphatidylinositol 30 kinase (PI3K)
inhibitor. This difference in sensitivities to two different agents
that target the same pathway may be due to the fact that these
agents show affinity for kinases other than the intended primary
target kinase. It is also known that KP372-1 inhibits kinases other
than Akt, such as CDK1, CK2, CSK, DNAPK, ERK1, GSK3b, LCK,
MEK1, PIM, PKA, PKC, and S6K, albeit at relatively high
concentrations (unpublished work from QLT). We have also
found that the NPA187 cell line showed higher levels of Akt
phosphorylation than WRO. This observation suggests that
NPA187 may be more dependent than WRO on the activation of
Akt for survival and proliferation.
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cell lines in vitro. Thyroid carcinoma cell lines NPA187 and WRO were
plated in a 96-well plate and treated with different concentrations of
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Figure 5 Effects of KP372-1 on the proliferation of thyroid carcinoma
cell lines in vitro. (A, B) Thyroid carcinoma cell lines NPA187 and WRO
were plated in six-well plates and treated with 30 and 60 nM KP372-1 for
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KP372-1 for 48 h. Cell proliferation was then measured by 3H-thymidine
incorporation. Results shown are representative of three experiments.
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Inhibition of Akt might be of great benefit to patients with
aggressive thyroid cancers, and support for the concept of
targeting Akt comes from many observations. First, more than
54% of human cancers have active Akt that is detectable in situ
(Bellacosa et al, 1991). Akt activation was identified in 10 of 10
follicular cancers, 26 of 26 papillary cancers, and two of 10
follicular variants of papillary cancers, but in only four of 66
normal tissue samples and two of 10 typical benign follicular
adenomas (Vasko et al, 2004). Second, pAkt expression was found
to be greatest in regions of capsular invasion and was localised to
the nucleus in follicular cancers and to the cytoplasm in papillary
cancers, except for invasive regions of papillary cancers, where it
localised to both compartments (Vasko et al, 2004). Thus, small-
molecule Akt inhibitors could have wide applicability as anticancer
drugs. Third, inhibition of the PI3K/Akt pathway by biochemical
or genetic means increases the efficacy of chemotherapy, radio-
therapy, or both, in vitro and in vivo (Hu et al, 2000; Brognard
et al, 2001; Bondar et al, 2002). Finally, several standard
chemotherapeutic and chemopreventive agents inhibit the PI3K/
Akt pathway when administered in vitro, and, in some cases,
inhibition of Akt is directly responsible for these agents’
cytotoxicity (West et al, 2002).
Despite the acknowledged need for Akt inhibitors, none is
widely available and none that inhibits the kinase activity of Akt is
in clinical evaluation. The current studies indicate that KP372-1
acts to inhibit Akt and has activity in cells with high levels of pAkt.
This is similar to other inhibitors of the PI3K/Akt pathway, such as
Wortmannin and LY294002. Wortmannin and LY294002 may have
limited clinical utility because they lack specificity and have
potential adverse side effects, poor pharmacological properties,
low stability, and poor solubility (West et al, 2002). Wortmannin
inhibits myosin light-chain kinase; phospholipases C, D, and A2;
and DNA-dependent protein kinase (West et al, 2002). LY294002
also inhibits the aryl hydrocarbon receptor, a ligand-activated
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using an in vitro kinase assay with GSK-b as a substrate. Results shown are
representative of three experiments.
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transcription factor (Guo et al, 2000). In vivo use of LY294002 in
mice has been associated with many adverse effects, including
death (Hu et al, 2002). Similarly, Wortmannin has demonstrated
hepatic and haematopoietic toxicity. Therefore, although Wort-
mannin and LY294002 inhibit the PI3K/Akt pathway, their
drawbacks raise doubts about their suitability as leading
candidates for additional development.
The major advantage of KP372-1 over Wortmannin and
LY294002 as PI3K inhibitors is its greater efficacy and the marked
induction of apoptosis in cancer cell lines. This may be due to its
targeting a central downstream molecule and also due to the
potential for a number of processes to bypass effects at the level of
PI3K. However, the final determination will be in terms of
therapeutic index, which will need to be evaluated in mice and
eventually humans. Indeed, a potential downside of Akt inhibitors
is toxicity because of the importance of Akt signalling in many
normal cellular processes such as insulin signalling, and the lack of
selectivity of the current Akt inhibitors including KP372-1 to
different Akt isoforms. Identifying kinase inhibitors that target the
ATP-binding site of a kinase can be fraught with specificity
problems because all kinases and many other molecules possess
ATP-binding sites. This was perhaps best observed with STI-571
(Gleevec, imatinib mesylate, Novartis Pharma, Basel, Switzerland),
a competitive inhibitor of the ATP-binding site of many kinases
(Klejman et al, 2002). The wide clinical application of STI-571 is
partially due to its ability to inhibit many kinases, including bcr–
abl, platelet-derived growth factor receptors, and c-Kit (Heinrich
et al, 2000; McGary et al, 2002; von Bubnoff et al, 2002). The
relatively nonspecific activity of STI-571 results in activity against
Kit and the PDGFR in gastrointestinal stromal tumours (GIST) and
against the PDGFR in hypereosinophilic syndrome. It is somewhat
surprising and fortuitous that the relative broad activity of STI-571
was not associated with toxicity.
In conclusion, thyroid cancer cell lines and well-differentiated
human tumour specimens showed high levels of Akt phosphoryla-
tion on Ser473 and high Akt activity levels, which supported the
findings of several other studies (Dahia et al, 1997; Liaw et al, 1997;
Ringel et al, 2001), indicating that the Akt signalling pathway plays
a role in thyroid cancer progression. In addition, specific
inhibition of Akt kinase activity by KP372-1 resulted in decreased
cell proliferation and induction of apoptosis of thyroid cancer cells
in vitro. Although anaplastic thyroid cell lines were included in
some of our experiments, our data lend support to the use of Akt
kinase inhibitor in well-differentiated thyroid carcinoma rather
than in anaplastic or poorly differentiated thyroid carcinomas.
These findings indicate that further preclinical evaluation of this
and other compounds targeting the PI3K/Akt pathway in well-
differentiated thyroid cancer is warranted.
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